Ann: Positive FDA Pre-IND meeting guides IHL-675A development, page-49

This absolute treasure of a stock is still a hidden gem for the most part.
The fact that the market cap is not yet above 500m means remarkably few people understand what will happen when this cannabinoid and psychedelics biotech company lists on a US exchange, ostensibly later this year.

Buying opportunity today, IMO. Now that the FDA has given positive guidance for all 125B's worth of addressable market in IHL-675A indications, I expect US listing news flow to be not far behind. I sold a parcel on the 20th at 29c. Time to buy back!